Technical Analysis for CALA - Calithera Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
6.68 | 2.77% | 0.18 |
CALA closed up 2.77 percent on Wednesday, March 20, 2019, on 1.97 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical CALA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 20 | Pocket Pivot | Bullish Swing Setup | 0.00% |
| Mar 20 | Upper Bollinger Band Walk | Strength | 0.00% |
| Mar 20 | Overbought Stochastic | Strength | 0.00% |
| Mar 20 | Upper Bollinger Band Touch | Strength | 0.00% |
| Mar 19 | Spinning Top | Other | 2.77% |
| Mar 19 | Calm After Storm | Range Contraction | 2.77% |
| Mar 19 | Upper Bollinger Band Walk | Strength | 2.77% |
| Mar 19 | Inside Day | Range Contraction | 2.77% |
| Mar 19 | Overbought Stochastic | Strength | 2.77% |
| Mar 18 | Pocket Pivot | Bullish Swing Setup | 1.52% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-07
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Cancer Treatment Of Cancer Solid Tumors Oncology Tumor Lymphoma Multiple Myeloma Targeted Therapy Anatomical Pathology Hematology Phosphoinositide 3 Kinase Inhibitor Lymphomas Leukemias
Medicine Biopharmaceutical Cancer Treatment Of Cancer Solid Tumors Oncology Tumor Lymphoma Multiple Myeloma Targeted Therapy Anatomical Pathology Hematology Phosphoinositide 3 Kinase Inhibitor Lymphomas Leukemias
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more CALA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 7.45 |
| 52 Week Low | 3.55 |
| Average Volume | 169,001 |
| 200-Day Moving Average | 4.9412 |
| 50-Day Moving Average | 5.1528 |
| 20-Day Moving Average | 5.955 |
| 10-Day Moving Average | 6.255 |
| Average True Range | 0.3673 |
| ADX | 43.14 |
| +DI | 31.6985 |
| -DI | 8.3828 |
| Chandelier Exit (Long, 3 ATRs ) | 5.7681 |
| Chandelier Exit (Short, 3 ATRs ) | 6.1419 |
| Upper Bollinger Band | 6.8444 |
| Lower Bollinger Band | 5.0656 |
| Percent B (%b) | 0.91 |
| BandWidth | 29.870697 |
| MACD Line | 0.4056 |
| MACD Signal Line | 0.3565 |
| MACD Histogram | 0.0491 |
| Fundamentals | Value |
|---|---|
| Market Cap | 236.98 Million |
| Num Shares | 35.5 Million |
| EPS | -1.14 |
| Price-to-Earnings (P/E) Ratio | -5.86 |
| Price-to-Sales | 47.73 |
| Price-to-Book | 3.36 |
| PEG Ratio | -0.25 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.27 | ||||
| Resistance 3 (R3) | 7.26 | 7.07 | 7.17 | ||
| Resistance 2 (R2) | 7.07 | 6.92 | 7.07 | 7.13 | |
| Resistance 1 (R1) | 6.87 | 6.83 | 6.97 | 6.88 | 7.10 |
| Pivot Point | 6.68 | 6.68 | 6.73 | 6.68 | 6.68 |
| Support 1 (S1) | 6.48 | 6.53 | 6.58 | 6.49 | 6.26 |
| Support 2 (S2) | 6.29 | 6.44 | 6.29 | 6.23 | |
| Support 3 (S3) | 6.09 | 6.29 | 6.19 | ||
| Support 4 (S4) | 6.10 |
